Journals
Consult the user guide
For assistance, please contact us
Consult the user guide
For assistance, please contact us
Add search criteria
Results: 1 - 30 of 62
2019-06-17 [p.5674]
— by Ms. Petitpas Taylor (Minister of Health) — Annual Report on the National Strategy for Alzheimer's Disease and Other Dementias for 2019, pursuant to the National Strategy for Alzheimer's Disease and Other Dementias Act, S.C. 2017, c. 19, s. 5. — Sessional Paper No. 8560-421-1225-01. (Pursuant to Standing Order 32(5), permanently referred to the Standing Committee on Health)
2019-04-29 [p.5180]
— Health Canada. — Sessional Paper No. 8520-421-307-01. (Pursuant to Standing Order 81(7), deemed referred to the Standing Committee on Health)
2019-04-11 [p.5155]
— Health Canada. — Sessional Paper No. 8520-421-307. (Pursuant to Standing Order 81(7), deemed referred to the Standing Committee on Health)
2019-03-20 [p.4887]
Ms. Murray (President of the Treasury Board), seconded by Ms. Chagger (Leader of the Government in the House of Commons), moved Motion No. 66, — That Vote 1, in the amount of $178,460,440, under Department of Health — Operating expenditures, in the Interim Estimates for the fiscal year ending March 31, 2020, be concurred in.
2019-03-20 [p.4887]
The question was put on Motion No. 66 and it was agreed to on the following division:
(Division No. 1140 -- Vote no 1140) - View vote details.
YEAS: 107, NAYS: 44
2019-03-20 [p.4888]
Ms. Murray (President of the Treasury Board), seconded by Ms. Chagger (Leader of the Government in the House of Commons), moved Motion No. 67, — That Vote 5, in the amount of $4,533,797, under Department of Health — Capital expenditures, in the Interim Estimates for the fiscal year ending March 31, 2020, be concurred in.
2019-03-20 [p.4888]
The question was put on Motion No. 67 and it was agreed to on the following division:
(Division No. 1141 -- Vote no 1141) - View vote details.
YEAS: 105, NAYS: 45
2019-03-20 [p.4889]
Ms. Murray (President of the Treasury Board), seconded by Ms. Chagger (Leader of the Government in the House of Commons), moved Motion No. 68, — That Vote 10, in the amount of $775,839,418, under Department of Health — Grants, contributions and payments to international financial institutions, in the Interim Estimates for the fiscal year ending March 31, 2020, be concurred in.
2019-03-20 [p.4889]
The question was put on Motion No. 68 and it was agreed to on the following division:
(Division No. 1142 -- Vote no 1142) - View vote details.
YEAS: 104, NAYS: 41
2019-03-20 [p.5038]
— by Ms. Petitpas Taylor (Minister of Health) — Service Fees Report of the Department of Health for 2017 to 2018, pursuant to the Service Fees Act, S.C. 2017, c. 20, sbs. 20. — Sessional Paper No. 8560-421-1187-01. (Pursuant to Standing Order 32(5), permanently referred to the Standing Committee on Health)
2019-02-21 [p.4617]
— by Ms. Petitpas Taylor (Minister of Health) — Report on the administration and operation of the Canada Health Act for the fiscal year ended March 31, 2018, pursuant to the Canada Health Act, R.S. 1985, c. C-6, s. 23. — Sessional Paper No. 8560-421-458-04. (Pursuant to Standing Order 32(5), permanently referred to the Standing Committee on Health)
2019-01-28 [p.4523]
Q-2129 — Mr. Dubé (Beloeil—Chambly) — With regard to Health Canada’s re-evaluation decisions, including RVD2017-01, Glyphosate, and the “Monsanto Papers”: (a) how many and which studies are currently being re-evaluated by Health Canada; (b) for each of the studies in (a), when did Health Canada make the decision to re-evaluate it; (c) has Health Canada verified the independence of the studies in (a); (d) if the answer to (c) is affirmative, what was the detailed process for verifying the independence of the studies; and (e) does Health Canada have information that approved independent studies were written by Monsanto and, if so, since what date, broken down by study? — Sessional Paper No. 8555-421-2129.
2018-12-04 [p.4406]
— by Ms. Petitpas Taylor (Minister of Health) — Framework on Palliative Care in Canada, pursuant to the Framework on Palliative Care in Canada Act, S.C. 2017, c. 28, sbs. 3(1). — Sessional Paper No. 8560-421-1150-01. (Pursuant to Standing Order 32(5), permanently referred to the Standing Committee on Health)
2018-11-19 [p.4283]
Q-1962 — Ms. Gladu (Sarnia—Lambton) — With regard to reports that Health Canada is considering shutting down or cutting funding to certain organizations, and that a gag order has been issued to the affected organizations not to discuss the matter, namely Mental Health Commission of Canada, Canadian Centre on Substance Use and Addiction, Canadian Agency for Drugs and Technologies in Health, Canadian Institute for Health Information, Canadian Foundation for Healthcare Improvement, Canada Health Infoway, Canadian Patient Safety Institute, Canadian Partnership Against Cancer: (a) why is the government reviewing the funding that these organizations receive; (b) why have each of the organizations been given a gag order; (c) was the Minister of Health’s office made aware of the gag order and, if so, on what date; (d) was the Office of the Prime Minister informed that a gag order was being issued and if so, on what date; (e) what is the complete list of organizations which were subject to the External Review of the Federally Funded Pan-Canadian Health Organizations; (f) has anyone from Health Canada, the Minister of Health’s office, or Deloitte instructed or advised any of the organizations subject to the review not to publicly discuss the review; (g) if the answer to (f) is affirmative, what are the details of any such non-disclosure clause or gag order including (i) who issued the order, (ii) date of the order, (iii) scope of the gag order; (h) have any of the organizations in (e) been told that they will lose their funding, in whole or in part, and if so, which organizations have been notified of this decision; and (i) for each organization whose funding is being eliminated or reduced, what is the rationale being used by the Minister of Health for the funding reduction? — Sessional Paper No. 8555-421-1962.
2018-11-05 [p.4231]
Q-1893 — Ms. Duncan (Edmonton Strathcona) — With regard to Health Canada’s notice of a recall for a list of Valsartan products supplied by Chinese corporation Zhejiang Huahai Pharmaceuticals: (a) on what date did Health Canada become aware of the contamination of these drugs with N-nitrosodimethylamine (NDMA); (b) was the recall issued at the request of Canadian authorities; (c) what is deemed a long-term exposure to this carcinogen; (d) if there was a delay in issuing the recall after Health Canada was informed of the contamination, what were the reasons for the delay in the public notice; (e) how was Health Canada made aware of the contamination of the valsartan medicines; (f) did Health Canada directly conduct any laboratory tests on these drugs to determine their safety before approving their use in Canada; (g) has Health Canada or any federal authority undertaken any investigations of the laboratory and manufacturing facilities of Zhejiang Huahai Pharmaceuticals; (h) why did Health Canada advise patients to continue taking the Valsartan products despite the knowledge it was contaminated with a carcinogen and who made that decision; (i) are any other products manufactured by Zhejiang Huahai Pharmaceuticals currently being distributed, sold or prescribed in Canada; (j) what actions has Health Canada taken to test alternative blood pressure medicines being prescribed in Canada to determine their safety; and (k) what information has been provided to Health Canada on adverse effects reported by Canadians taking Valsartan? — Sessional Paper No. 8555-421-1893.
2018-09-17 [p.3955]
Q-1880 — Mr. Barlow (Foothills) — With regard to the Minister of Health: (a) what are the details of all memorandums or briefing notes on the front of package regulations, including (i) date, (ii) sender, (iii) recipient, (iv) title, (v) summary, (vi) file number, (vii) position on front of package proposal (i.e. supportive or opposed); (b) what are the peer-reviewed scientific studies and analyses used in the consideration of the proposed regulation, broken down by (i) title of article, (ii) date of publication, (iii) author; (c) what does the government estimate as the annual cost for the next two, five and 10 years to the industry to implement these changes, broken down by sector, including (i) primary agriculture, (ii) meat processors, (iii) seafood processors, (iv) dairy producers, (v) chicken farmers and processors, (vi) turkey farmers and producers, (vii) corn farmers and producers, (viii) soy farmers and producers (ix) sugar beat farmers and producers; (d) by what percentage in the next five, ten, twenty and forty years is the government expecting a reduction of 2018 rates of the following health concerns due to front of package labelling, (i) heart disease, (ii) obesity rates, (iii) diabetes, (iv) cancers; and (e) what are the details of all correspondence by foreign government on front of package labelling, broken down by (i) date, (ii) sender, (iii) recipient, (iv) title, (v) summary, (vi) file number (vii) position on front of package proposal (i.e. supportive or opposed)? — Sessional Paper No. 8555-421-1880.
2018-09-17 [p.3958]
— by Ms. Petitpas Taylor (Minister of Health) — Interim Order Respecting the Epinephrine Auto-injectors , pursuant to the Food and Drugs Act, R.S. 1985, c. F-27, sbs. 30.1(6) and (7). — Sessional Paper No. 8560-421-1018-01. (Pursuant to Standing Order 32(5), permanently referred to the Standing Committee on Health)
2018-08-22 [p.3912]
— by Ms. Petitpas Taylor (Minister of Health) — Reports of the Department of Health for the fiscal year ended March 31, 2018, pursuant to the Access to Information Act and to the Privacy Act, R.S. 1985, c. A-1 and P-21, sbs. 72(2). — Sessional Paper No. 8561-421-629-04. (Pursuant to Standing Order 108(3)(h)(v), permanently referred to the Standing Committee on Access to Information, Privacy and Ethics)
2018-06-05 [p.3470]
Q-1661 — Mr. Kmiec (Calgary Shepard) — With regard to Health Canada’s Special Access Program (SAP) that considers requests for access to drugs that are otherwise unavailable to Canadians from medical practitioners to treat serious or life-threatening conditions: (a) what is the aggregate number of applications that have been received by the SAP in the 2015, 2016, and 2017 calendar years; (b) of all SAP applications received in the 2015, 2016, and 2017 calendar years, what is the number of repeat applications for the same drug or health product; (c) for drugs that have received multiple requests in the 2015, 2016, and 2017 calendar years, what are the drug names and the number of requests they have each received; (d) what is the total number of SAP applications that have been approved in the 2015, 2016, and 2017 calendar years; (e) what is the total number of SAP applications that have been rejected in the 2015, 2016, and 2017 calendar years; (f) what are the alphabetized names of all drugs and health products that have been approved by the SAP program in the 2015, 2016, and 2017 calendar years; (g) what are the alphabetized names of all drugs and health products that have been rejected by the SAP program in the 2015, 2016, and 2017 calendar years; (h) how many times has the procedures manual that assessors refer to in administration of the SAP been updated and what are these updates for the 2015, 2016, and 2017 calendar years; (i) what are the measures undertaken by Health Canada to ensure its workers have a good understanding of the medical conditions they're reviewing as part of SAP applications; and (j) what is the aggregate cost of administering the SAP to the government for the 2016 fiscal year? — Sessional Paper No. 8555-421-1661.
2018-05-03 [p.3189]
Q-1565 — Mr. Falk (Provencher) — With regard to Health Canada's decisions taken with respect to Mifegymiso: (a) is Health Canada capturing data on the safety and efficacy of Mifegymiso on Canadian patients; (b) if the answer to (a) is affirmative, (i) how is the data being obtained, (ii) what data is being obtained, (iii) will the data be made public; (c) will Health Canada conduct a Canadian post-market study independent of the drug manufacturer Linepharma on the safety of Mifegymiso; (d) if the answer to (c) is affirmative, (i) on what date will the study commence, (ii) on what date will the study end, (iii) what methodology will be used, (iv) where will the study be conducted; (e) will Health Canada ensure that the drug manufacturer Linepharma conducts a Phase IV Observational Study on the safety of Mifegymiso on Canadian women; and (f) if the answer (e) is affirmative, (i) on what date will the study commence, (ii) on what date will the study end, (iii) what methodology will be used, (iv) where will the study be conducted? — Sessional Paper No. 8555-421-1565.
2018-04-16 [p.3083]
— Health Canada. — Sessional Paper No. 8520-421-215. (Pursuant to Standing Order 81(7), deemed referred to the Standing Committee on Health)
2018-04-16 [p.3095]
Q-1533 — Mr. Viersen (Peace River—Westlock) — With regard to studies conducted by, or on behalf of, Health Canada, since January 1, 2016: (a) what studies have been done on the side effects of Mifegymiso, including (i) date, (ii) methodology, (iii) who conducted the study, (iv) location, (v) finding; and (b) what data has been collected on the side effects of Mifegymiso, broken down by (i) each of the known side effects of Mifegymiso, (ii) Health Canada's estimate on the number of Canadians affected by each of the known side effects of Mifegymiso? — Sessional Paper No. 8555-421-1533.
2018-03-22 [p.2832]
Mr. Brison (President of the Treasury Board), seconded by Mr. Morneau (Minister of Finance), moved Motion No. 21, — That Vote 1c, in the amount of $34,377,223, under Department of Health — Operating expenditures, in the Supplementary Estimates (C) for the fiscal year ending March 31, 2018, be concurred in.
2018-03-22 [p.2832]
The question was put on Motion No. 21 and it was agreed to on the following division:
(Division No. 489 -- Vote no 489) - View vote details.
YEAS: 173, NAYS: 66
2018-03-22 [p.2834]
Mr. Brison (President of the Treasury Board), seconded by Mr. Morneau (Minister of Finance), moved Motion No. 22, — That Vote 5c, in the amount of $540,000, under Department of Health — Capital expenditures, in the Supplementary Estimates (C) for the fiscal year ending March 31, 2018, be concurred in.
2018-03-22 [p.2834]
The question was put on Motion No. 22 and it was agreed to on the following division:
(Division No. 490 -- Vote no 490) - View vote details.
YEAS: 172, NAYS: 62
2018-03-22 [p.2974]
Ms. Chagger (Leader of the Government in the House of Commons) for Mr. Brison (President of the Treasury Board), seconded by Mr. Morneau (Minister of Finance), moved Motion No. 63, — That Vote 1, in the amount of $194,606,063, under Department of Health — Operating expenditures, in the Interim Estimates for the fiscal year ending March 31, 2019, be concurred in.
2018-03-22 [p.2974]
The question was put on Motion No. 63 and it was agreed to on the following division:
(Division No. 601 -- Vote no 601) - View vote details.
YEAS: 143, NAYS: 42
2018-03-22 [p.2976]
Ms. Chagger (Leader of the Government in the House of Commons) for Mr. Brison (President of the Treasury Board), seconded by Mr. Morneau (Minister of Finance), moved Motion No. 64, — That Vote 5, in the amount of $6,551,315, under Department of Health — Capital expenditures, in the Interim Estimates for the fiscal year ending March 31, 2019, be concurred in.
Results: 1 - 30 of 62 | Page: 1 of 3

1
2
3
>
>|
Export As: XML CSV RSS

For more data options, please see Open Data